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Stand first 
The self-controlled case series (SCCS) method is an epidemiological study design for which individuals 
act as their own control i.e. comparisons are made within-individuals. Hence, only individuals who have 
experienced an event are included and all time invariant confounding is eliminated. The temporal 
association between a transient exposure and an event is estimated. SCCS was originally developed for 
evaluation of vaccine safety, but has since been applied in a range of settings where we may not have   
exact information on the size of the population at risk  or it can be difficult to identify an appropriate 
comparison group, for example for studies of adverse effects of drug treatments. We provide an 
overview of the SCCS method, examples of its use, we discuss limitations, assumptions and potential 
biases that can arise where assumptions are not met along with solutions and examples of good 
practice.  
 
  
Introduction 
In 1951, Richard Doll and Austin Bradford Hill, wrote to all registered physicians in the United Kingdom 
to obtain information about their smoking habits. This research was groundbreaking as they were one of 
the first teams to demonstrate a link between smoking and various diseases (1). Since then, 
epidemiological study designs, such as cohort and case-control studies, have been widely applied in 
medical research (w1). There are several situations, however, where standard epidemiological study 
designs fall short. For example, in the research of adverse effects of vaccines, it can be difficult to 
identify suitable comparison groups (e.g. if most of the population receives the vaccine). Likewise, for 
studies on hospital data we may not have information on the exact catchment areas and hence we 
struggle to find suitable controls for cases of a particular event. In these situations the self-controlled 
case series (SCCS) method provides an alternative epidemiological study design to investigate the 
association between a transient exposure and an outcome event. The SCCS method is a case-only 
method; it has the advantages that no separate controls are required and any fixed confounder is 
automatically controlled for.(2,3) 
In this paper we provide an overview of SCCS methodology and some examples of how the method has 
been applied in order to give a flavour of the potentials of SCCS. As for any epidemiological study design 
the SCCS method has some assumptions. We discuss these and identify the key limitations and potential 
biases. 
 
Self-controlled case series (SCCS) methodology 
The SCCS method aims to estimate a relative incidence, which compares the incidence of adverse events 
within periods of hypothesized excess risk due to exposure with incidence during all other time. Asking 
‘when?’ rather than ‘who?’ becomes the key question. Precise timings are needed, so the SCCS method 
is best suited to acute events and transient exposures for which periods of exposure risk can be clearly 
defined. Only those who have experienced an event (cases), can contribute any information on when 
the event occurred, so only data on these individuals need to be collected.   
After having identified cases, the first step in setting up the data for SCCS is to define observation 
periods, these are the study periods for each individual, over which a full history on the timing of events 
and exposures are available. The next step is to define the periods when exposure may have had an 
impact within the observation period, for example, a fixed number of days after receipt of a first drug 
prescription or a vaccine; these are known as exposure risk periods. All remaining time within the 
observation period constitutes baseline exposure periods, to which the exposure risk periods will be 
compared. SCCS studies may include multiple exposure risk periods as it may be necessary to capture 
either multiple doses or varying exposure-related risk using several risk periods (which may be of same 
or different lengths). Observation periods can be further divided according to age groups, seasons 
and/or any other relevant time-varying factors so they can be accounted for in the analysis. The third 
step is to ‘map’ events in relation to the different periods identified. Once the data is set up, the final 
step is to estimate the relative incidence (RI) of events in pre-specified exposure risk periods compared 
to baseline periods, whilst taking into account the effect of any time-varying confounders such as age 
groups (w2).   
In Figure 1 we illustrate the SCCS setup for an individual with two exposure risk periods and five age 
groups (panel A) and use this individual to illustrate the output of an SCCS model (panels B, C and D). 
Figure 1 here 
Comparisons are not made between-individuals as in a cohort or case-control study; estimation is 
within-individuals. Any factor or characteristic that remains constant over observation periods cancels 
out of the SCCS model, this includes individual-specific underlying risk and factors such as sex, ethnicity 
and deprivation. It is in this sense that the SCCS model is self-controlled.   
Conceptually, the SCCS method builds on the principles of a cohort study (w1). Individuals are followed 
through time, the exposure history is fixed and events are random. However, the SCCS method differs in 
that the total number of events occurring within an individual’s observation period is fixed and follow-up 
is not censored at an event. Hence all exposures occurring within the observation period - both before 
and after individuals have experienced the event - are included in the analysis.  
A worked example which  illustrates how to fit the SCCS model is included in the web materials (w2) and 
further details of the theory and model fitting are given in Whitaker et al.(3). Below we present two 
examples of studies that applied the SCCS method. Figure 2 provides a schematic overview of the SCCS 
study design for each of the studies and the key results. 
 
Example applications of the SCCS method in medical research 
Example 1: A possible drug interaction between clopidogrel and Proton Pump Inhibitors (PPI) 
Douglas et al. (4) used both a cohort and SCCS approach to study a drug interaction between clopidogrel 
and proton pump inhibitors (PPI) on the risk of myocardial infarction (MI). The cohort analysis found an 
increased risk of MI when clopidogrel was combined with a PPI, supporting the notion that an 
interaction between the two drugs would reduce the effectiveness of clopidogrel (RI 1.30 (1.12-1.50). 
However, the effect was non-specific as an increased risk of non-vascular death was also seen, 
suggesting underlying confounding was difficult to account for. The SCCS analysis examined whether the 
risk of MI was increased in the period when PPI was added to clopidogrel treatment (Figure 2). Thus, the 
observation period was the duration of clopidogrel treatment, and the exposure risk periods were 
periods of PPI treatment, which varied in length and number amongst the study participants. SCCS 
found no increased risk for MI (RI 0.75 (0.55-1.01), suggesting that the underlying confounding had been 
dealt with through this design. 
 
Example 2: Inflamations and Myocardial Infarction or Stroke 
Smeeth et al. (5) aimed to evaluate the association between inflammation and myocardial infarction or 
stroke. The exposures included inflammatory stimuli: vaccinations and acute infection. SCCS was used 
because of concerns that people receiving vaccinations may differ from those unvaccinated and likewise 
people acquiring infections may differ from uninfected people in ways that are difficult to measure and 
account for. Exposure risk periods were defined up to 91 days following the recording of either an 
infection or a vaccination, and were further subdivided to allow the relative incidence of events to vary 
over this period (Figure 2) An increased risk of both MI and stroke was seen over the risk period 
following either a systemic respiratory tract infection or a urinary tract infection, with the strongest 
effect in the first 7 days. The risk was still elevated up to 91 days, but appeared to be returning towards 
baseline. No increased risk was seen following influenza, tetanus or pneumococcal vaccinations.(5) 
Figure 2 provides the incidence rate ratios for MI following respiratory tract infections.  
 
SCCS assumptions 
As for other epidemiological study designs the SCCS model makes certain assumptions that should be 
met to provide valid and unbiased estimates. Below we outline these assumptions. Table 1 provides a 
summary of assumption violations that can arise, the solutions and examples of good practice against 
each.  
 
A. Occurrence of an event should not (appreciably) affect subsequent exposures 
A key assumption is that subsequent exposures should not appreciably be affected by previous events. 
However, this may often be the case. For example, occurrence of an event may delay exposure, the 
event may be a contra-indication for treatment or the event may result in, or is death. This assumption 
also means that the event itself should not determine the timing of the end of the observation period.  
Ignoring this assumption may potentially produce biased estimates, but there are various 
extensions/moderations to the SCCS method that can mitigate potential biases (Table 1). Note that 
independent causes of death/end of observation do not cause bias. 
Temporary delay or increase in exposure after an event 
If the event only temporarily delays exposure this will result in a deficit of events in the period just 
before exposure that reduces the overall incidence in the baseline period. This results in relative 
incidence estimates that are biased upwards. One way to correct for this bias is to include a `pre-
exposure period’ (Table 1.1) just before an exposure.(3) A pre-exposure period can similarly be applied if 
there is a short-term increase in the probability of exposure after an event (Table 1.2), which would 
otherwise bias estimates toward the null. A pre-exposure period was included in the clopidogrel and PPI 
interaction example anticipating that the chance of being started on a PPI could be temporarily altered 
by having an MI, this is illustrated in figure 2.(4) The pre-exposure period ‘trick’ only works for short-
term delay (in relation to the length of observation). If there is long-term delay in exposure after events 
the methods in the next paragraph may be applied. 
No exposure can occur after the event e.g. if the outcome is death 
If the outcome is death exposures that might have otherwise occurred after the event will never be 
known. This is also true if the exposure history is only collected up until the time of the event or if the 
event is a contra-indication to exposure (Table 1.3). If a fixed length exposure can only occur once, a 
simple solution is to define the observation to begin with the start of exposure and finish with the end of 
study that would have applied had death/censoring not occurred.(3,6) This a priori definition of the 
observation period means that only exposed cases are included, and if the exposure risk period is of a 
fixed length then the full exposure history is always known even beyond the time of death/censoring. 
Alternatively, there is an extension of the SCCS method which produces unbiased estimates given these 
scenarios.(7)  
If the outcome is death, but the exposure is external to the case and fully observable after death e.g. a 
weather phenomenon, the standard SCCS method can be applied using the full planned observation 
period, had the case not died. 
Event increases the probability of death  
If the event carries high mortality, such as myocardial infarction or stroke, then there is a chance that 
observation periods could be cut short as a direct result of the event. Resulting bias can be in either 
direction (Table 1.4). If the event mortality is low, bias will be negligible and the situation ignorable. 
Comparison of results from fitting SCCS models to all cases and excluding those who died can be made; 
major differences would suggest bias. Bias may be corrected by fitting an extension that involves 
modelling post-event survival times.(8)  
B. Event rates are constant within intervals 
Event rates are assumed to be constant within each defined period. While such an assumption is often 
unrealistic, it is convenient, makes relative incidence estimates easy to interpret and is commonly used 
in other study designs. Control of strong age or season effects is important and SCCS models with 
greater flexibility have been developed.(9,10)  
C. Events must be independently recurrent or rare  
The SCCS method was developed for independent recurrent events, but it has been demonstrated that 
the method is valid for non-recurrent events when the risk of occurrence over the study period in the 
entire cohort is 10% or less.(8) A test for independence has been developed. (11) If events are 
dependent a simple solution is to study just first events (Table 1.5). An extension for which events may 
depend on the prior event history exists.(12) 
 
Final remarks  
With this paper we have sought to demonstrate how the self-controlled case series method provides an 
alternative to standard epidemiological designs when investigating associations between a transient 
exposure and an outcome event  A major strength of the SCCS is that it is self-controlled and accounts 
for any factor or characteristics that remains constant over observation period. Thus, where uncertainty 
over the control of fixed confounders exists in a cohort or case-control study, SCCS may provide a 
superior design, given careful thought is made to applying the methodology correctly.  
Summary 
 The self-controlled case series method provides an alternative to established epidemiological 
designs. 
 SCCS is best suited to acute recurrent or non-recurrent events and transient exposures for which 
precise timings are available. 
 Estimation is within-individuals and no separate controls are required, hence the method is self-
controlled and time invariant factors are cancelled out.  
 Follow up is not censored at the event, so when events can impact on subsequent exposure, 
care must be taken to ensure analyses are carried out that eliminate or minimize bias. 
 
Linked information 
The Open University host a website for the Self-controlled Case series methodology with example 
datasets and code for analysis in Stata, SAS, R, Genstat and GLIM. 
A link to the tutorial by Whitaker et al.(3) can also be found on this website. 
http://statistics.open.ac.uk/sccs/index.htm 
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Table 1: Violation of assumptions, impact and solutions with examples of good practice. 
Problem Solution Example 
1) Event temporarily 
decreases the 
probability of 
exposure 
Include a pre-
exposure period 
Stowe et al studied the risk of infections after 
mumps, measles and rubella (MMR) vaccination. 
Vaccination is delayed when a child has an infection; 
a 14-day pre-exposure period was included to allow 
for this. (13) 
2) Event temporarily 
increases the 
probability of 
exposure 
Include a pre-
exposure period 
Gibson et al studied the association between 
prescription medications and motor vehicle crashes. 
A 4-week pre-exposure period was included since 
some medications may be used to treat anxiety or 
pain caused by the crash. (14) 
3) No exposure can 
occur (or is observed) 
after the event  
For single exposures 
that cannot be 
repeated, begin the 
observation period 
at exposure, so only 
exposed cases are 
included. End 
observation at the 
planned end.  
 
Hubbard et al studied the association between first 
bupropion prescription and sudden death. The 
observation period began with date of first 
prescription and ended (beyond death) with the date 
of last data collection for the cohort. At the time, 
bupropion could only be prescribed as a single course 
of treatment.(6) 
 
 For single or 
multiple exposures, 
use the method 
outlined in 
Farrington et al. (7) 
Dodd et al studied the association between influenza 
vaccination and Guillain Barré Syndrome (GBS). Some 
practitioners will not vaccinate previous GBS 
patients.(15) Various analyses were performed: 
standard SCCS, vaccinated cases only, and the 
method outlined in Farrington et al. (7) 
4) Event increases the 
probability of death 
Undertake suitable 
tests or sensitivity 
analyses excluding 
cases who died as a 
result of the event. 
 
Langan et al studied the risk of stroke following 
herpes zoster infection. A sensitivity analysis was 
performed excluding cases who died within 90 days 
of stroke, findings were not modified.(16) 
 
 If necessary, use the 
methods outlined in 
Farrington et al.(8) 
to adjust for bias. 
Brauer et al. studied the association between 
antipsychotic drugs and myocardial infarction using 
both the methods outlined in Farrington et al. (8) and 
a standard SCCS analysis. There was little difference 
in results.(17) 
5) Recurrences of an 
event are not 
independent 
Study the first event 
only 
Recurrence of stroke is not independent of the first 
occurrence, so only a first stroke event can be 
studied. In a study on the risk of stroke, Langan et al. 
began the observation period 12 months into follow 
up time to ensure first stroke events had been 
correctly identified.(16) 
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Figure 1 Graphic illustration of the SCCS model output using a fictive individual with two exposure risk 
periods and five age groups.  
Panel A: An individual observation period segmented by two exposure risk periods (red boxes, labelled 
exposure risk status 1) and five age groups (blue boxes, labelled 0 to 4). The baseline categories for age 
and exposure are labelled age group 0 and exposure risk status 0 respectively. 
Panel B: Exposure-related relative incidences. Note for the baseline category the relative incidence is 1 
and the exposure relative incidence is arbitrarily set to 1.8. 
Panel C: Age-related relative incidence on age groups 1-4 compared with age group 0. The age relative 
incidences for age groups 1-4 have been set to 2, 1.5, 1.2 and 0.5 respectively. 
Panel D: Overall profile of relative incidence on each of the nine intervals, this is the age-related relative 
incidence multiplied by the exposure-related relative incidence.   
  
Figure 2: Typical Observation periods, risk periods and headline results for two examples of applied SCCS 
 
 
